Crosstalk of the Heart and Periphery: Skeletal and Cardiac Muscle as Therapeutic Targets in Heart Failure

References

• Sullivan M J, Green H J, Cobb F R. Altered skeletal muscle metabolic response to exercise in chronic heart failure. Circulation 1991; 84: 1597–607
   PubMed Web of Science ®Google Scholar
• Packer M. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248–54
   PubMed Web of Science ®Google Scholar
• Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray?. J Am Coll Cardiol 1993; 22(Suppl A)119A–26A
   PubMedGoogle Scholar
• Dracup K, Baker D W, Dunbar S B, et al. Management of heart failure II. Counseling, education and lifestyle modifications. JAMA 1994; 272: 1442–6
   PubMed Web of Science ®Google Scholar
• Sullivan M J, Higginbotham M B, Cobb F R. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise tolerance. Circulation 1989; 79: 324–9
   PubMed Web of Science ®Google Scholar
• Coats A JS, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure: exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992; 85: 2119–31
   PubMed Web of Science ®Google Scholar
• Cohn J N, Johnson G R, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardio-thoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87(Suppl VI)VI-5–16
   Google Scholar
• Colucci W S, Sonnenblick E H, Adams K F, et al. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. J Am Coll Cardiol 1993; 22(Suppl A)113A–8A
   Google Scholar
• Lipicky R J, Packer M. Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993; 22(Suppl A)179A–84A
   PubMedGoogle Scholar
• Eichhom E J, Bristow M R. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996; 94: 2285–96
   PubMed Web of Science ®Google Scholar
• Cohn J N, Bristow M R, Chien K R, et al. Report of the National Heart, Lung and Blood Institute special emphasis panel on heart failure research. Circulation 1997; 95: 766–70
   PubMed Web of Science ®Google Scholar
• Feldman A M, Bristow M R, Parmley W W, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 32(9)149–55
   Google Scholar
• Cowley A J, Rowley J M, Stainer K, Hampton J R. The effect of angiotensin converting enzyme inhibitor, enalapril, on exercise tolerance and abnormalities of limb blood flow and respiratory function in patients with severe heart failure. Eur Heart J 1993; 14: 964–8
   PubMedGoogle Scholar
• Hasenfuss G, Holubarsch C, Heiss H W, et al. Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone. Circulation 1989; 80: 51–64
   PubMedGoogle Scholar
• Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during calcium-sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997; 61: 596–607
   PubMed Web of Science ®Google Scholar
• Ingwall J S. Is cardiac failure a consequence of decreased energy reserve?. Circulation 1993; 87(Suppl VII)VII-58–62
   Google Scholar
• Franclosa J A, Park M, Levine T B. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 1981; 47: 33–9
   PubMedGoogle Scholar
• Massie B M, Kramer B, Haughom F. Acute- and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance. Circulation 1981; 64: 1218–26
   PubMedGoogle Scholar
• Maskin C S, Forman R, Sonnenblick E H, Frlshman W H, LeJemtel T H. Failure of dobutamine to increase capacity despite hemodynamic improvement in severe chronic heart failure. Am J Cardiol 1983; 51: 177–82
   PubMed Web of Science ®Google Scholar
• Savin W M, Haskell W L, Schroeder J S, Stinson E B. Cardiorespiratory responses of cardiac transplant patients to graded, symptom-limited exercise. Circulation 1980; 62: 55–60
   PubMed Web of Science ®Google Scholar
• Saltln B. Hemodynamic adaptions to exercise. Am J Cardiol 1985; 55: 42D–7D
   Google Scholar
• Rowell L B. Control of blood flow to dynamically active muscles. Human Cardiovascular Control, L B Rowell. Oxford University Press, New York 1993; 255–301
   Google Scholar
• Magnusson G, Kaijser L, Sylven C, Karlberg K -E, Isberg B, Saltin B. Peak skeletal muscle perfusion is maintained in patients with chronic heart failure when only a small muscle mass is exercised. Cardiovasc Res 1997; 33: 297–306
   PubMed Web of Science ®Google Scholar
• Andersen P, Saltin B. Maximal perfusion of skeletal muscle in man. J Physiol 1985; 233–49
   PubMedGoogle Scholar
• Wilson S R, Groves J, Rayos G. Circulatory status and response to cardiac rehabilitation in patients with heart failure. Circulation 1996; 94: 1567–72
   PubMedGoogle Scholar
• Gordon A. On Improvement of Exercise Tolerance in Patients with Chronic Heart Failure. Thesis, Karolinska Institute, Stockholm 1996
   Google Scholar
• Drexler H. Reduced exercise tolerance in chronic heart failure and its relationship to neurohumoral factors. Eur Heart J 1991; 12(Suppl C)21–8
   PubMedGoogle Scholar
• Wilson J R, Mancini D M. Factors contributing to the exercise limitation of heart failure. J Am Coll Cardiol 1993; 22(Suppl A)93A–8A
   PubMedGoogle Scholar
• Kiilavuori K, Toivonen L, Naveri H, Leinonen H. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. Eur Heart J 1995; 16: 490–5
   PubMed Web of Science ®Google Scholar
• Tyni-Lenne R, Gordon A, Sylven C. Improved health-related quality of life in moderate chronic heart failure following submaximal exercising of leg muscle. J Cardiac Failure 1996; 2: 111–7
   PubMedGoogle Scholar
• Cohn J N. Physiological variables as markers for symptoms, risk, and interventions in heart failure. Circulation 1993; 87(Suppl VII)VII-110–4
   Google Scholar
• Packer M, Bristow M R, Cohn J N, et al. Effect of carve-dilol on morbidity and mortality in chronic heart failure. N Engl J Med 1996; 334: 1349–55
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci W, Sacker-Bernstein J D, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation 1996; 94: 2793–9
   PubMed Web of Science ®Google Scholar
• Demopoulos L, Yeh M, Gentilucci M, et al. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Circulation 1997; 95: 1764–7
   PubMedGoogle Scholar
• Pitt B, Segal R, Martinez F A, et al. Randomized trial of losartan vs. captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349: 747–52
   PubMed Web of Science ®Google Scholar
• Colucci W S. Apoptosis in the heart. N Eng J Med 1996; 335: 1224–6
   PubMed Web of Science ®Google Scholar
• Ver Donck L. Calcium-sensitizing drugs: positive inotropy by enhanced sensitivity of the contractile apparatus to calcium. Cardiovasc Drug Rev 1996; 14: 185–212
   Google Scholar